RECOMBINANT ERYTHROPOIETIN REVERSES POLYMORPHONUCLEAR GRANULOCYTE DYSFUNCTION IN IRON-OVERLOADED DIALYSIS PATIENTS

被引:63
作者
BOELAERT, JR [1 ]
CANTINIEAUX, BF [1 ]
HARIGA, CF [1 ]
FONDU, PG [1 ]
机构
[1] UNIV LIBRE BRUXELLES, HOP ST PIERRE, DEPT HAEMATOL, B-1000 BRUSSELS, BELGIUM
关键词
DIALYSIS; ERYTHROPOIETIN; GRANULOCYTE FUNCTION; IRON OVERLOAD;
D O I
10.1093/ndt/5.7.504
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Iron overload increases the risk of bacterial infection in dialysis patients, partly by impairing functions of the polymorphonuclear granulocytes (PMNs). PMN defence was studied sequentially in haemodialysis patients with transfusional haemosiderosis, treated for 6 +/- 1.5 months (n = 8) to 13 +/- 1.7 months (n = 4) with recombinant human erythropoietin (rHuEpo). Over this period, signs of iron overload (increased serum ferritin and serum iron) improved, and stainable iron disappeared in PMNs. Simultaneously, phagocytosis of Yersinia enterocolitica by PMNs improved. The decrease in serum ferritin was significantly related to the improved phagocytosis. Killing of Y. enterocolitica by PMNs also improved. It is anticipated that rHuEpo therapy in iron-overloaded dialysis patients could decrease the incidence of bacterial infection by improving PMN functions in these patients.
引用
收藏
页码:504 / 507
页数:4
相关论文
共 15 条
[1]   IRON OVERLOAD IN HEMODIALYSIS-PATIENTS INCREASES THE RISK OF BACTEREMIA - A PROSPECTIVE-STUDY [J].
BOELAERT, JR ;
DANEELS, RF ;
SCHURGERS, ML ;
MATTHYS, EG ;
GORDTS, BZ ;
VANLANDUYT, HW .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1990, 5 (02) :130-134
[2]  
BOELAERT JR, 1989, NEW ENGL J MED, V321, P190
[3]   THE ROLE OF IRON OVERLOAD IN YERSINIA-ENTEROCOLITICA AND YERSINIA-PSEUDOTUBERCULOSIS BACTEREMIA IN HEMODIALYSIS-PATIENTS [J].
BOELAERT, JR ;
VANLANDUYT, HW ;
VALCKE, YJ ;
CANTINIEAUX, B ;
LORNOY, WF ;
VANHERWEGHEM, JL ;
MOREILLON, P ;
VANDEPITTE, JM .
JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (02) :384-387
[4]  
CANTINIEAUX B, 1988, J LAB CLIN MED, V111, P524
[5]  
CANTINIEAUX B, 1987, EUR J HAEMATOL, V39, P28
[6]   CORRECTION OF THE ANEMIA OF END-STAGE RENAL-DISEASE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - RESULTS OF A COMBINED PHASE-I AND PHASE-II CLINICAL-TRIAL [J].
ESCHBACH, JW ;
EGRIE, JC ;
DOWNING, MR ;
BROWNE, JK ;
ADAMSON, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (02) :73-78
[7]   THE ANEMIA OF CHRONIC RENAL-FAILURE - PATHO-PHYSIOLOGY AND THE EFFECTS OF RECOMBINANT ERYTHROPOIETIN [J].
ESCHBACH, JW ;
BOURDEAU, J ;
COE, F ;
TOBACK, G ;
COHEN, JJ ;
POCHEDLY, C ;
GARELLA, S ;
LAU, K ;
BUSHINSKY, D ;
SPRAGUE, S ;
KUMAR, S ;
SACKS, P ;
KATHPALIA, S ;
RICHTER, M ;
MADIAS, NE ;
HARRINGTON, JT .
KIDNEY INTERNATIONAL, 1989, 35 (01) :134-148
[8]   EFFECTS OF IRON AND DESFERRIOXAMINE ON INFECTIONS WITH YERSINIA-ENTEROCOLITICA [J].
ROBINSBROWNE, RM ;
PRPIC, JK .
INFECTION AND IMMUNITY, 1985, 47 (03) :774-779
[9]  
SEIFERT A, 1987, Q J MED, V65, P1015
[10]   DEFEROXAMINE DOES NOT INCREASE THE RISK FOR BACTEREMIA IN HEMODIALYSIS-PATIENTS [J].
TIELEMANS, C ;
BOELAERT, J ;
VERGAUWE, P ;
VANROOST, G ;
SEGAERT, M ;
VANFRACHEN, B ;
LENCLUD, C .
NEPHRON, 1989, 53 (03) :276-277